Unknown OBSERVATIONAL NCT03228368

The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients

The Predicted Potential of Quantitative T Cell Repertoire(TCR) Analysis Using Next-generation Sequencing (NGS) in Anti-PD-L1 Treatment in Non Small Cell Lung（NSCLC) Cancer Patients

Sponsor: First Affiliated Hospital of Zhejiang University

Conditions Non-Small Cell Lung Cancer

Interventions Atezolizumab (MPDL3280A)

Updated 7 times since 2017 Last updated: Jul 21, 2017 Started: Mar 1, 2017 Primary completion: Mar 1, 2018 Completion: Dec 1, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03228368, this observational or N/A phase trial focuses on Non-Small Cell Lung Cancer and remains ongoing. Sponsored by First Affiliated Hospital of Zhejiang University, it has been updated 7 times since 2017, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status
Apr 2019 — Jan 2021 [monthly]

Unknown Status

Status: Recruiting → Unknown Status
Jun 2018 — Apr 2019 [monthly]

Recruiting

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Recruiting

Phase: NA → None
Aug 2017 — Apr 2018 [monthly]

Recruiting NA

First recorded

Mar 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

First Affiliated Hospital of Zhejiang University
Geneplus-Beijing Co. Ltd.
Hoffmann-La Roche

Data source: First Affiliated Hospital of Zhejiang University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China